Diazoxide how supplied storage and handling
| Diazoxide |
|---|
| PROGLYCEM® FDA Package Insert |
| Indications and Usage |
| Dosage and Administration |
| Contraindications |
| Warnings and Precautions |
| Adverse Reactions |
| Drug Interactions |
| Use in Specific Populations |
| Overdosage |
| Description |
| Clinical Pharmacology |
| Nonclinical Toxicology |
| How Supplied/Storage and Handling |
| Labels and Packages |
| Clinical Trials on Diazoxide |
| ClinicalTrials.gov |
Editor-In-Chief: C. Michael Gibson, M.S., M.D. [1]; Associate Editor(s)-in-Chief: Sheng Shi, M.D. [2]
How Supplied Storage and Handling
PROGLYCEM® (diazoxide capsules, USP), 50 mg, half opaque orange and half clear capsules, branded in black with BNP 6000: bottle of 100 (NDC 0575-6000-01).
PROGLYCEM® suspension, 50 mg/mL, a chocolate-mint flavored suspension; bottle of 30 ml (NDC 0575-6200-30), with dropper calibrated to deliver 10, 20, 30, 40 and 50 mg diazoxide. Shake well before each use. Protect from light. Store in carton until contents are used. Store in light resistant container as defined in the USP. Store PROGLYCEM® Capsules and Suspension at 25°C (77°F) excursions permitted 15°-30°C (59-86°F). [See USP Controlled Room Temperature].
Rx only
Manufactured by: TEVA PHARMACEUTICALS USA
Sellersville, PA 18960
Manufactured for: Teva Select Brands, Horsham, PA 19044 Division of Teva Pharmaceuticals USA
Rev. 2/2012[1]
References
- ↑ "PROGLYCEM (DIAZOXIDE) SUSPENSION [TEVA GLOBAL RESPIRATORY RESEARCH LLC]". Retrieved 26 February 2014.
Template:Nonsympatholytic vasodilatory antihypertensives Template:Other therapeutic products Template:Channel openers